Free Trial
→ From the man who predicted 2008 crash… (From Porter & Company) (Ad)tc pixel Free DYN Stock Alerts

Dyne Therapeutics (DYN) Financials

Dyne Therapeutics logo
$18.28 -0.16 (-0.87%)
Closing price 04:00 PM Eastern
Extended Trading
$18.28 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Dyne Therapeutics

Annual Income Statements for Dyne Therapeutics

This table shows Dyne Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -15 -59 -149 -168 -236 -317 -446
Consolidated Net Income / (Loss)		 -15 -59 -149 -168 -236 -317 -446
Net Income / (Loss) Continuing Operations		 -15 -59 -149 -168 -236 -317 -446
Total Pre-Tax Income 		-15 -59 -149 -168 -236 -317 -446
Total Operating Income		 -14 -59 -150 -171 -242 -344 -468
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 14 59 150 171 242 344 468
Selling, General & Admin Expense		 2.79 13 29 28 31 62 70
Research & Development Expense		 11 45 121 143 211 281 398
Total Other Income / (Expense), net		 -1.03 0.11 0.73 2.86 6.23 26 22
Interest Expense		 0.00 0.40 - - 0.00 0.00 6.19
Interest & Investment Income		 0.29 0.06 0.74 2.92 7.64 27 30
Other Income / (Expense), net		 -1.32 0.45 -0.01 -0.05 -1.42 -0.45 -1.70
Basic Earnings per Share		 ($6.08) ($4.13) ($2.93) ($3.23) ($3.95) ($3.37) ($3.47)
Weighted Average Basic Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M 128.44M
Diluted Earnings per Share		 ($6.08) ($4.13) ($2.93) ($3.23) ($3.95) ($3.37) ($3.47)
Weighted Average Diluted Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M 128.44M
Weighted Average Basic & Diluted Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M 128.44M

Quarterly Income Statements for Dyne Therapeutics

This table shows Dyne Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -60 -67 -66 -65 -97 -90 -115 -111 -108 -112 -121
Consolidated Net Income / (Loss)		 -60 -67 -66 -65 -97 -90 -115 -111 -108 -112 -121
Net Income / (Loss) Continuing Operations		 -60 -67 -66 -65 -97 -90 -115 -111 -108 -112 -121
Total Pre-Tax Income 		-60 -67 -66 -65 -97 -90 -115 -111 -108 -112 -121
Total Operating Income		 -62 -68 -69 -72 -106 -97 -122 -116 -114 -116 -125
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 62 68 69 72 106 97 122 116 114 116 125
Selling, General & Admin Expense		 7.02 8.84 25 9.70 13 15 16 17 17 21 24
Research & Development Expense		 55 59 45 62 93 82 106 99 97 95 101
Total Other Income / (Expense), net		 2.06 1.05 3.51 6.86 8.53 7.57 7.01 4.93 5.85 4.17 4.42
Interest Expense		 - - - 0.00 0.00 - 0.00 0.09 2.90 - 4.20
Interest & Investment Income		 2.19 1.75 3.00 7.05 9.28 7.59 7.10 6.63 8.48 7.66 8.76
Other Income / (Expense), net		 -0.13 -0.70 0.51 -0.19 -0.74 -0.03 -0.09 -1.60 0.28 -0.29 -0.13
Basic Earnings per Share		 ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97) ($0.76) ($0.69) ($0.73)
Weighted Average Basic Shares Outstanding		 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M
Diluted Earnings per Share		 ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97) ($0.76) ($0.69) ($0.73)
Weighted Average Diluted Shares Outstanding		 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M
Weighted Average Basic & Diluted Shares Outstanding		 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M

Annual Cash Flow Statements for Dyne Therapeutics

This table details how cash moves in and out of Dyne Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.51 288 -100 -29 -51 313 458
Net Cash From Operating Activities		 -12 -47 -120 -154 -188 -292 -403
Net Cash From Continuing Operating Activities		 -12 -47 -120 -154 -188 -292 -403
Net Income / (Loss) Continuing Operations		 -15 -59 -149 -168 -236 -317 -446
Consolidated Net Income / (Loss)		 -15 -59 -149 -168 -236 -317 -446
Depreciation Expense		 0.27 0.70 1.09 1.68 1.67 1.67 2.05
Amortization Expense		 0.00 0.08 2.58 1.28 -1.10 -3.60 -1.84
Non-Cash Adjustments To Reconcile Net Income		 1.35 6.14 14 17 21 47 46
Changes in Operating Assets and Liabilities, net		 1.41 5.11 12 -5.38 26 -19 -3.40
Net Cash From Investing Activities		 -1.65 -46 -138 87 83 -204 -29
Net Cash From Continuing Investing Activities		 -1.65 -46 -138 87 83 -204 -29
Purchase of Property, Plant & Equipment		 -1.65 -1.16 -3.62 -3.07 -0.73 -2.38 -21
Purchase of Investments		 0.00 -45 -237 -121 -44 -317 -181
Sale and/or Maturity of Investments		 - 0.00 102 211 128 116 172
Net Cash From Financing Activities		 20 381 158 37 54 810 890
Net Cash From Continuing Financing Activities		 20 381 158 37 54 810 890
Repayment of Debt		 0.00 -10 0.00 - 0.00 0.00 -0.56
Issuance of Debt		 0.00 9.94 0.00 - 0.00 0.00 148
Issuance of Common Equity		 0.00 246 157 37 52 773 735
Other Financing Activities, net		 0.00 -0.42 0.58 0.53 1.95 37 8.00
Cash Interest Paid		 0.00 0.33 0.00 - 0.00 0.00 4.34

Quarterly Cash Flow Statements for Dyne Therapeutics

This table details how cash moves in and out of Dyne Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -37 -8.66 150 336 -76 -97 37 13 89 320 -140
Net Cash From Operating Activities		 -51 -35 -79 -55 -75 -84 -106 -95 -91 -112 -145
Net Cash From Continuing Operating Activities		 -51 -35 -78 -55 -75 -84 -106 -95 -91 -112 -145
Net Income / (Loss) Continuing Operations		 -60 -67 -66 -65 -97 -90 -115 -111 -108 -112 -121
Consolidated Net Income / (Loss)		 -60 -67 -66 -65 -97 -90 -115 -111 -108 -112 -121
Depreciation Expense		 0.43 0.40 0.39 0.40 0.44 0.45 0.50 0.50 0.52 0.52 0.55
Non-Cash Adjustments To Reconcile Net Income		 5.04 5.90 20 6.86 8.88 11 13 10 11 11 13
Changes in Operating Assets and Liabilities, net		 4.50 26 -33 4.24 14 -5.09 -3.60 5.64 5.87 -11 -38
Net Cash From Investing Activities		 13 26 -180 11 -19 -16 1.46 6.77 -38 0.98 -2.39
Net Cash From Continuing Investing Activities		 13 26 -182 11 -19 -16 1.46 6.77 -38 0.98 -2.39
Purchase of Property, Plant & Equipment		 -0.17 -0.08 -0.19 -0.86 -0.25 -1.08 -0.98 -0.06 -19 -0.48 -0.22
Purchase of Investments		 -9.58 - -181 -26 -57 -53 -66 -41 -47 -27 -64
Sale and/or Maturity of Investments		 23 26 0.00 38 38 38 68 48 28 28 62
Net Cash From Financing Activities		 0.45 0.15 408 380 18 3.64 141 101 217 431 7.06
Net Cash From Continuing Financing Activities		 0.45 0.15 408 380 18 3.64 141 101 217 431 7.06
Repayment of Debt		 - - - - - - 0.00 - - -0.01 -0.03
Issuance of Debt		 - - 324 - - - 0.00 - - 49 0.00
Issuance of Common Equity		 - -0.00 74 376 - - 141 - 216 378 -0.42
Other Financing Activities, net		 0.45 0.15 11 4.28 18 3.64 0.59 1.97 2.07 3.37 7.52
Cash Interest Paid		 - - - - - - 0.00 - - 2.52 3.63

Annual Balance Sheets for Dyne Therapeutics

This table presents Dyne Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 16 353 426 306 165 691 1,187
Total Current Assets		 15 349 382 266 129 659 1,127
Cash & Equivalents		 15 301 201 172 122 435 893
Short-Term Investments		 0.00 44 176 84 1.47 207 217
Prepaid Expenses		 0.13 3.77 5.82 9.58 6.28 17 16
Plant, Property, & Equipment, net		 1.49 1.95 4.68 5.95 4.78 5.40 24
Total Noncurrent Assets		 0.19 2.30 39 35 31 27 36
Other Noncurrent Operating Assets		 0.19 2.30 39 35 31 27 36
Total Liabilities & Shareholders' Equity		 16 353 426 306 165 691 1,187
Total Liabilities		 2.40 11 57 54 74 61 215
Total Current Liabilities		 2.36 11 29 28 51 42 51
Accounts Payable		 1.26 3.44 4.03 5.26 23 6.56 8.08
Accrued Expenses		 1.10 7.53 21 18 23 31 38
Other Current Liabilities		 - 0.00 3.89 4.61 4.72 4.85 5.00
Total Noncurrent Liabilities		 0.04 0.00 29 26 23 19 164
Long-Term Debt		 - - - - - 0.00 149
Capital Lease Obligations		 - - - - - - 15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14 342 368 252 91 630 972
Total Preferred & Common Equity		 14 342 368 252 91 630 972
Preferred Stock		 27 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -13 342 368 252 91 630 972
Common Stock		 6.35 422 597 650 724 1,580 2,368
Retained Earnings		 -20 -79 -228 -397 -633 -950 -1,396
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.03 -0.27 -0.57 0.00 0.01 0.48

Quarterly Balance Sheets for Dyne Therapeutics

This table presents Dyne Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 340 289 251 205 522 826 769 721 729 867 1,080
Total Current Assets		 298 249 213 168 488 792 736 690 698 806 1,021
Cash & Equivalents		 136 181 168 130 272 608 532 472 485 574 753
Short-Term Investments		 156 57 40 28 182 171 192 205 199 218 219
Prepaid Expenses		 6.10 11 5.44 10 35 13 13 12 14 14 49
Plant, Property, & Equipment, net		 5.48 5.57 5.36 5.11 4.58 5.02 4.90 5.75 5.68 24 24
Total Noncurrent Assets		 37 34 33 32 30 29 28 26 23 37 35
Other Noncurrent Operating Assets		 37 34 33 32 30 29 28 26 23 37 35
Total Liabilities & Shareholders' Equity		 340 289 251 205 522 826 769 721 729 867 1,080
Total Liabilities		 53 47 45 53 44 51 63 52 158 175 215
Total Current Liabilities		 26 22 20 30 22 30 43 34 41 60 51
Accounts Payable		 6.97 8.77 2.72 3.55 7.21 1.89 6.16 7.02 14 12 11
Accrued Expenses		 13 8.17 13 21 10 23 32 22 22 43 29
Other Current Liabilities		 5.49 4.64 4.71 4.71 4.76 4.78 4.81 5.11 5.00 5.04 11
Total Noncurrent Liabilities		 27 25 24 24 22 21 20 18 116 115 164
Long-Term Debt		 - - - - - - - - 99 99 149
Capital Lease Obligations		 - - 24 24 - 21 - 18 - 16 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 287 242 207 152 478 775 706 669 571 692 865
Total Preferred & Common Equity		 287 242 207 152 478 775 706 669 571 692 865
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 287 242 207 152 478 775 706 669 571 692 865
Common Stock		 605 683 713 718 1,176 1,539 1,565 1,734 1,747 1,975 2,382
Retained Earnings		 -316 -441 -506 -566 -698 -763 -860 -1,065 -1,176 -1,284 -1,517
Accumulated Other Comprehensive Income / (Loss)		 -1.16 -0.20 -0.06 -0.01 -0.13 -0.24 0.48 0.24 0.25 0.50 -0.14

Annual Metrics And Ratios for Dyne Therapeutics

This table displays calculated financial ratios and metrics derived from Dyne Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - 142,824,687.00
DEI Adjusted Shares Outstanding		 - - - - - - 142,824,687.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -3.12
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -9.68 -41 -105 -120 -170 -241 -328
Return On Investment Capital (ROIC_SIMPLE)		 - - - -47.42% -185.68% -38.22% -29.23%
Earnings before Interest and Taxes (EBIT)		 -15 -58 -150 -171 -244 -344 -470
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -57 -146 -168 -243 -346 -470
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -39 -100 -124 -141 -260 -351
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -0.60 -2.95 -8.37 -3.65 -32 -12 10
Increase / (Decrease) in Invested Capital		 0.00 -2.35 -5.43 4.73 -28 19 23
Book Value per Share		 ($5.48) $7.53 $7.15 $4.86 $1.49 $6.19 $6.81
Tangible Book Value per Share		 ($5.48) $7.53 $7.15 $4.86 $1.49 $6.19 $6.81
Total Capital		 14 342 368 252 91 630 1,121
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 149
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 149
Net Debt		 -15 -345 -377 -256 -123 -642 -962
Capital Expenditures (CapEx)		 1.65 1.16 3.62 3.07 0.73 2.38 21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.23 -7.19 -23 -19 -45 -25 -35
Debt-free Net Working Capital (DFNWC)		 12 338 354 238 78 617 1,076
Net Working Capital (NWC)		 12 338 354 238 78 617 1,076
Net Nonoperating Expense (NNE)		 5.18 18 44 48 66 77 118
Net Nonoperating Obligations (NNO)		 -15 -345 -377 -256 -123 -642 -962
Total Depreciation and Amortization (D&A)		 0.27 0.78 3.67 2.96 0.57 -1.93 0.21
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.13) ($2.93) ($3.23) ($3.95) ($3.37) ($3.47)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 51.46M 51.64M 56.34M 59.68M 94.14M 128.44M
Adjusted Diluted Earnings per Share		 $0.00 ($4.13) ($2.93) ($3.23) ($3.95) ($3.37) ($3.47)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 51.46M 51.64M 51.98M 59.68M 94.14M 128.44M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.13) ($2.93) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 14.40M 50.90M 51.98M 59.68M 94.14M 128.44M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.68 -41 -105 -120 -170 -241 -328
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Dyne Therapeutics

This table displays calculated financial ratios and metrics derived from Dyne Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 142,824,687.00 142,824,687.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 142,824,687.00 142,824,687.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.78 -0.85
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 -49.64% -70.59% -50.20% -8.93% -71.56% -43.02% -79.56% -63.54% -6.19% - -1.86%
EBIT Growth		 -47.56% -69.28% -50.29% -7.52% -70.52% -42.03% -78.38% -62.69% -6.87% - -2.41%
NOPAT Growth		 -47.29% -68.61% -52.11% -7.83% -69.67% -43.46% -76.95% -60.91% -7.88% - -2.37%
Net Income Growth		 -45.49% -71.63% -48.57% -0.31% -61.31% -34.37% -75.72% -70.28% -11.24% - -4.76%
EPS Growth		 -23.75% -50.68% -3.85% 35.19% 3.03% 18.18% -29.63% -38.57% 20.83% - 30.48%
Operating Cash Flow Growth		 -18.22% -19.92% -67.43% 1.39% -47.48% -140.92% -34.83% -72.60% -21.64% - -36.86%
Free Cash Flow Firm Growth		 -166.58% 41.44% -211.13% 41.04% 37.87% -354.44% -2.40% -7.66% -197.57% - -89.89%
Invested Capital Growth		 0.00% -771.93% 558.11% -26.31% -202.28% 60.92% -60.42% -193.54% 184.50% - 482.94%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 7.02% -9.39% -0.12% -6.16% -46.44% 8.81% -25.69% 4.26% 3.31% - -7.37%
EBIT Q/Q Growth		 7.02% -9.60% -0.38% -5.10% -47.46% 8.71% -26.07% 4.14% 3.22% - -7.72%
NOPAT Q/Q Growth		 6.69% -8.70% -2.17% -4.06% -46.83% 8.09% -26.02% 5.38% 1.64% - -7.88%
Net Income Q/Q Growth		 7.23% -10.68% 1.48% 0.83% -49.19% 7.81% -28.83% 3.90% 2.54% - -7.95%
EPS Q/Q Growth		 8.33% -11.11% 26.36% 13.58% -37.14% 6.25% -16.67% 7.62% 21.65% - -5.80%
Operating Cash Flow Q/Q Growth		 9.06% 30.82% -124.35% 30.14% -36.02% -13.01% -25.56% 10.57% 4.14% - -29.59%
Free Cash Flow Firm Q/Q Growth		 18.20% 68.65% -259.97% 36.12% 13.80% -129.28% 18.89% 32.84% -137.85% - -12.59%
Invested Capital Q/Q Growth		 -24.45% -279.41% 177.05% -29.44% -204.86% 31.45% 178.04% -266.75% 194.73% - 119.41%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 96.49% 97.44% 95.63% 90.23% 91.28% 92.18% 94.20% 94.44% 95.10% - 96.37%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -273.78% -137.31% -71.50% -52.46% -68.69% -88.03% -64.01% -61.32% -60.66% - -58.89%
Cash Return on Invested Capital (CROIC)		 -1,894.77% 0.00% -1,465.59% -900.80% 0.00% 0.00% -1,538.60% 0.00% -2,270.67% - -1,137.01%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -273.78% -137.31% -71.50% -52.46% -68.69% -88.03% -64.01% -61.32% -60.66% - -58.89%
Return on Equity Simple (ROE_SIMPLE)		 -136.89% 0.00% -53.84% -33.23% -41.74% 0.00% -54.88% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -44 -47 -48 -50 -74 -68 -86 -81 -80 -81 -88
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -24.75% -10.16% -4.98% -3.13% -5.40% -5.64% -5.34% -4.43% -4.04% - -4.52%
Return On Investment Capital (ROIC_SIMPLE)		 - -51.90% -10.13% - - -10.79% -12.47% -12.09% -9.88% -7.25% -8.52%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -62 -68 -69 -72 -106 -97 -122 -117 -114 -116 -125
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -62 -68 -68 -73 -107 -98 -123 -117 -113 -116 -125
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.60 8.94 4.87 3.98 5.11 3.81 1.77 1.89 2.60 - 2.99
Price to Tangible Book Value (P/TBV)		 3.60 8.94 4.87 3.98 5.11 3.81 1.77 1.89 2.60 - 2.99
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 23.26 0.00 76.43 134.50 0.00 0.00 54.02 0.00 73.30 - 31.50
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.15 0.00 0.00 0.03 0.00 0.00 0.03 0.17 0.17 - 0.19
Long-Term Debt to Equity		 0.15 0.00 0.00 0.03 0.00 0.00 0.03 0.17 0.17 - 0.19
Financial Leverage		 -0.88 -1.10 -0.96 -0.96 -1.00 -1.06 -0.97 -1.00 -1.00 - -0.96
Leverage Ratio		 1.35 1.37 1.13 1.10 1.14 1.19 1.08 1.15 1.17 - 1.17
Compound Leverage Factor		 1.30 1.34 1.08 0.99 1.04 1.09 1.02 1.09 1.11 - 1.13
Debt to Total Capital		 13.39% 0.00% 0.00% 2.63% 0.00% 0.00% 2.65% 14.74% 14.30% - 15.91%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 13.39% 0.00% 0.00% 2.63% 0.00% 0.00% 2.65% 14.74% 14.30% - 15.91%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 86.61% 100.00% 100.00% 97.37% 100.00% 100.00% 97.35% 85.26% 85.70% - 84.09%
Debt to EBITDA		 -0.11 0.00 0.00 -0.08 0.00 0.00 -0.05 -0.22 -0.26 - -0.35
Net Debt to EBITDA		 0.63 0.00 0.00 2.78 0.00 0.00 1.66 1.32 1.50 - 1.72
Long-Term Debt to EBITDA		 -0.11 0.00 0.00 -0.08 0.00 0.00 -0.05 -0.22 -0.26 - -0.35
Debt to NOPAT		 -0.16 0.00 0.00 -0.11 0.00 0.00 -0.07 -0.32 -0.37 - -0.50
Net Debt to NOPAT		 0.89 0.00 0.00 3.99 0.00 0.00 2.37 1.90 2.15 - 2.45
Long-Term Debt to NOPAT		 -0.16 0.00 0.00 -0.11 0.00 0.00 -0.07 -0.32 -0.37 - -0.50
Altman Z-Score		 2.11 0.48 30.33 36.03 33.24 22.11 12.09 2.41 4.69 - 5.96
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.67 2.53 21.83 26.63 17.02 15.60 20.35 16.83 13.47 - 19.92
Quick Ratio		 5.32 2.41 20.28 26.18 16.73 15.20 20.00 16.49 13.23 - 18.97
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -61 -19 -69 -44 -38 -87 -71 -48 -113 -104 -135
Operating Cash Flow to CapEx		 -30,300.60% -42,690.24% -41,118.85% -6,402.33% -29,497.63% -7,845.12% -10,794.39% -157,838.33% -473.18% - -65,575.57%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -506.23 -38.97 - -32.02
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,007.48 -31.26 - -34.49
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,008.12 -37.87 - -34.54
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 18 -32 25 17 -18 -12 9.70 -16 15 10 57
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 18 -28 21 -6.17 -36 19 -15 -33 33 23 47
Enterprise Value (EV)		 412 693 1,873 2,326 2,883 1,755 524 497 1,123 - 1,781
Market Capitalization		 547 816 2,327 3,084 3,606 2,398 1,183 1,082 1,800 - 2,589
Book Value per Share		 $2.49 $1.49 $5.83 $8.87 $7.03 $6.19 $5.91 $5.03 $4.86 $6.81 $5.24
Tangible Book Value per Share		 $2.49 $1.49 $5.83 $8.87 $7.03 $6.19 $5.91 $5.03 $4.86 $6.81 $5.24
Total Capital		 176 91 478 796 706 630 687 670 807 1,121 1,029
Total Debt		 24 0.00 0.00 21 0.00 0.00 18 99 115 149 164
Total Long-Term Debt		 24 0.00 0.00 21 0.00 0.00 18 99 115 149 164
Net Debt		 -134 -123 -454 -758 -724 -642 -659 -585 -676 -962 -809
Capital Expenditures (CapEx)		 0.17 0.08 0.19 0.86 0.25 1.08 0.98 0.06 19 0.48 0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -19 -45 12 -16 -31 -25 -22 -27 -45 -35 -2.38
Debt-free Net Working Capital (DFNWC)		 139 78 466 763 693 617 656 656 746 1,076 970
Net Working Capital (NWC)		 139 78 466 763 693 617 656 656 746 1,076 970
Net Nonoperating Expense (NNE)		 17 19 17 15 23 22 30 30 28 31 33
Net Nonoperating Obligations (NNO)		 -134 -123 -454 -758 -724 -642 -659 -588 -676 -962 -809
Total Depreciation and Amortization (D&A)		 0.07 0.21 0.39 -0.87 -0.54 -0.39 -0.11 0.04 0.16 0.13 0.55
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97) ($0.76) ($0.69) ($0.73)
Adjusted Weighted Average Basic Shares Outstanding		 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M
Adjusted Diluted Earnings per Share		 ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97) ($0.76) ($0.69) ($0.73)
Adjusted Weighted Average Diluted Shares Outstanding		 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M
Normalized Net Operating Profit after Tax (NOPAT)		 -44 -47 -48 -50 -74 -68 -86 -81 -80 -81 -88
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,248.81 -39.12 - -29.85
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -862.27 -27.45 - -20.87
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,249.45 -45.73 - -29.90
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -862.91 -34.06 - -20.92
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Dyne Therapeutics (NASDAQ:DYN) has shown a consistent pattern of heavy R&D and operating expenses coupled with ongoing losses, while financing activities in 2025 have markedly boosted liquidity. Below is a concise four-year view focused on the latest four years of quarterly data, highlighting the key trends for retail investors.

  • Liquid balance strengthened by financing in 2025. Net cash from financing activities was positive in every 2025 quarter, totaling about $430.97 million in Q4 2025, $217.33 million in Q3 2025, $100.77 million in Q2 2025, and $141.24 million in Q1 2025, feeding liquidity despite ongoing losses.
  • Substantial equity financings in 2025. Issuance of Common Equity contributed heavily to the funding runway, with about $378.15 million raised in Q4 2025 and $215.80 million in Q3 2025.
  • Robust liquidity position by late 2025. Cash & equivalents stood at $573.6 million and short-term investments at $218.3 million in Q3 2025, placing total highly liquid assets near $792 million and supporting near-term liquidity needs.
  • Strong equity base relative to liabilities. Total equity was about $691.8 million (Q3 2025) versus total liabilities of $175.3 million, indicating a solid equity cushion and relatively low leverage.
  • Asset sales contributed to cash in 2025. The company generated cash from the sale/maturity of investments in multiple quarters (e.g., about $28.1–$28.2 million in Q3 and Q4 2025), aiding liquidity through asset sales.
  • Large overall asset base continues to grow. Total assets were about $867 million by Q3 2025, up from around $728–$731 million earlier in 2025, reflecting a growing balance sheet alongside the liquidity build.
  • No material long-term debt spike yet. Long-term debt hovered around $99 million in 2025 quarters, keeping liabilities manageable relative to the sizable equity base.
  • Revenue remains minimal in the period observed. Total revenue across many quarters is effectively zero, signaling that the business is in a pre-revenue phase and relies on financing for operating needs.
  • Persistent quarterly losses from operations. Net income (and net income attributable to common shareholders) remained negative in every 2022–2025 quarter, with Q4 2025 net income around -$111.96 million and Q3 2025 around -$108.04 million.
  • Cash flow from operations consistently negative. Net cash from continuing operating activities was negative in all 2025 quarters (e.g., -$111.87 million in Q4 2025, -$90.84 million in Q3 2025, -$94.70 million in Q2 2025, -$105.89 million in Q1 2025), indicating ongoing cash burn from core operations.
  • Share dilution and negative earnings per share persist. Weighted average shares outstanding rose through 2025 (e.g., ~141.8 million in Q3 2025), with basic and diluted earnings per share remaining negative (e.g., -$0.76 in Q3 2025 and -$0.69 in Q4 2025), highlighting ongoing dilution without current profitability.
05/14/26 06:16 PM ETAI Generated. May Contain Errors.

Dyne Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Dyne Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Dyne Therapeutics' net income appears to be on an upward trend, with a most recent value of -$446.21 million in 2025, rising from -$14.86 million in 2019. The previous period was -$317.42 million in 2024. View Dyne Therapeutics' forecast to see where analysts expect Dyne Therapeutics to go next.

Dyne Therapeutics' total operating income in 2025 was -$468.18 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $468.18 million

Over the last 6 years, Dyne Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Dyne Therapeutics' total liabilities were at $214.83 million at the end of 2025, a 249.9% increase from 2024, and a 8,851.2% increase since 2019.

In the past 6 years, Dyne Therapeutics' cash and equivalents has ranged from $14.63 million in 2019 to $893.37 million in 2025, and is currently $893.37 million as of their latest financial filing in 2025.

Over the last 6 years, Dyne Therapeutics' book value per share changed from -5.48 in 2019 to 6.81 in 2025, a change of -224.1%.


Related Companies

Financial statements for NASDAQ:DYN last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel
Musk's acquisition pattern points to ONE stock
Musk needed solar - he acquired SolarCity. Needed data - he bought Twitter. The pattern is clear: when a suppl...
Behind the Markets | Sponsoredtc pixel
Trump Just Named His Secret AI Project. It's Called "Golden Dawn."
Behind a hidden government lab in Tennessee, 40,000 scientists are reportedly finishing work on an AI system d...
InvestorPlace | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel